Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Actos · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Pioglitazone HCl Tablets 45 mg |
| 2 | ACTIVE_COMPARATOR | Actos® Tablets 45 mg |
| Name | Type | Description |
|---|---|---|
| Pioglitazone HCl Tablets 45 mg | DRUG | 45mg, single dose fed |
| Actos® Tablets 45 mg | DRUG | 45mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...
Actos is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials evaluating the drug in healthy individuals. Actos is being developed by Viatris Inc. (NASDAQ: VTRS).
Actos is being developed by Viatris Inc., a global healthcare company traded on NASDAQ under the ticker VTRS. The drug is currently in Phase 1 clinical development, with two completed trials in healthy volunteers.
Actos is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy volunteers in the United States. The drug is investigational and has not been approved by regulatory authorities.
Actos has two completed Phase 1 clinical trials: NCT00649012, a food study comparing pioglitazone HCl tablets 45 mg to Actos tablets 45 mg, and NCT00649558, a fasting study with the same comparison. Both trials enrolled healthy adults aged 18 years and older in the United States.
Actos is a brand name for pioglitazone hydrochloride. The clinical trials for Actos compare pioglitazone HCl tablets to Actos tablets, confirming they are the same drug substance. Actos is being developed by Viatris Inc. (NASDAQ: VTRS).